Fifth Third Wealth Advisors LLC Purchases New Position in Repligen Co. (NASDAQ:RGEN)

Fifth Third Wealth Advisors LLC purchased a new stake in Repligen Co. (NASDAQ:RGEN) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 2,165 shares of the biotechnology company’s stock, valued at approximately $273,000.

Other institutional investors have also recently made changes to their positions in the company. YHB Investment Advisors Inc. bought a new position in shares of Repligen in the 1st quarter valued at about $26,000. Lazard Asset Management LLC lifted its stake in Repligen by 206.1% in the first quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 136 shares during the last quarter. Benjamin F. Edwards & Company Inc. lifted its stake in Repligen by 152.1% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 242 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 146 shares during the last quarter. Principal Securities Inc. bought a new stake in Repligen in the fourth quarter worth about $48,000. Finally, GAMMA Investing LLC lifted its stake in Repligen by 183.4% in the second quarter. GAMMA Investing LLC now owns 479 shares of the biotechnology company’s stock worth $60,000 after purchasing an additional 310 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Analyst Ratings Changes

Several brokerages have issued reports on RGEN. JPMorgan Chase & Co. raised their price objective on shares of Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 31st. Royal Bank of Canada reissued an “outperform” rating and issued a $190.00 price objective on shares of Repligen in a research note on Wednesday, July 31st. Deutsche Bank Aktiengesellschaft raised shares of Repligen from a “hold” rating to a “buy” rating and decreased their price objective for the stock from $180.00 to $155.00 in a research note on Wednesday, June 26th. UBS Group decreased their price objective on shares of Repligen from $205.00 to $185.00 and set a “buy” rating for the company in a research note on Wednesday, July 31st. Finally, Stephens reissued an “overweight” rating and issued a $170.00 price objective on shares of Repligen in a research note on Tuesday, July 30th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, Repligen presently has an average rating of “Moderate Buy” and an average price target of $189.57.

Insider Activity at Repligen

In related news, CEO Anthony Hunt acquired 2,000 shares of the stock in a transaction dated Friday, June 14th. The stock was acquired at an average cost of $124.08 per share, for a total transaction of $248,160.00. Following the completion of the purchase, the chief executive officer now owns 165,177 shares of the company’s stock, valued at approximately $20,495,162.16. The purchase was disclosed in a document filed with the SEC, which is available through this link. In other Repligen news, CEO Anthony Hunt bought 2,000 shares of the firm’s stock in a transaction that occurred on Friday, June 14th. The stock was bought at an average cost of $124.08 per share, for a total transaction of $248,160.00. Following the completion of the transaction, the chief executive officer now directly owns 165,177 shares of the company’s stock, valued at approximately $20,495,162.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Martin D. Madaus bought 1,615 shares of the firm’s stock in a transaction that occurred on Friday, June 14th. The shares were acquired at an average price of $124.94 per share, with a total value of $201,778.10. Following the completion of the transaction, the director now directly owns 4,613 shares of the company’s stock, valued at $576,348.22. The disclosure for this purchase can be found here. 1.20% of the stock is currently owned by corporate insiders.

Repligen Trading Down 2.8 %

Shares of Repligen stock traded down $4.35 on Thursday, hitting $148.60. 39,452 shares of the company traded hands, compared to its average volume of 652,575. The stock’s 50 day moving average price is $137.80 and its 200-day moving average price is $163.60. The company has a current ratio of 6.65, a quick ratio of 5.56 and a debt-to-equity ratio of 0.26. Repligen Co. has a 52 week low of $110.45 and a 52 week high of $211.13. The company has a market cap of $8.32 billion, a PE ratio of 611.82, a PEG ratio of 5.27 and a beta of 0.95.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, July 30th. The biotechnology company reported $0.33 earnings per share for the quarter, meeting the consensus estimate of $0.33. The firm had revenue of $154.07 million during the quarter, compared to the consensus estimate of $154.11 million. Repligen had a negative net margin of 0.32% and a positive return on equity of 3.36%. The company’s revenue was down 3.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.53 earnings per share. Equities research analysts predict that Repligen Co. will post 1.45 EPS for the current year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.